Trial Profile
Pharmacokinetics of Abt-493 and Abt-530 given alone or in combination in Healthy Caucasian, Chinese, and Japanese Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2017
Price :
$35
*
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors AbbVie
- 11 Aug 2017 Results of this and one another phase I study published in the Journal of Clinical Pharmacology.
- 07 Jul 2015 New trial record